SCHEMBL1015657

SCHEMBL1015657

Cc1ccc(-c2cccc3cccnc23)cc1NC(=O)COCC(=O)Nc1ccc(Cl)cc1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.52
MAPT P10636 3/20 0.52
TP53 P04637 2/20 0.52
HSD17B10 Q99714 2/20 0.52
NPSR1 Q6W5P4 1/20 0.52
PPARG P37231 1/20 0.51
SERPINE1 P05121 4/20 0.51
POLB P06746 2/20 0.51
G6PD P11413 1/20 0.51
ALDH1A1 P00352 4/20 0.45
RXFP1 Q9HBX9 3/20 0.45
KDM4E B2RXH2 2/20 0.45
THRB P10828 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
BLM P54132 1/20 0.44
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1017185 0.99 HPGD (0.51) HPGDMAPTTP53HSD17B10NPSR1
SCHEMBL1015922 0.92 PPARG (0.51) HPGDMAPTTP53HSD17B10NPSR1
SCHEMBL1012800 0.81 KDM4E (0.59) MAPTHSD17B10SERPINE1POLBG6PD
SCHEMBL1015691 0.79 ALDH1A1 (0.52) MAPTTP53HSD17B10SERPINE1POLB
SCHEMBL1013571 0.79 SERPINE1 (0.57) HPGDMAPTNPSR1SERPINE1POLB
SCHEMBL1015626 0.78 RXFP1 (0.53) MAPTTP53HSD17B10SERPINE1POLB
SCHEMBL1013898 0.78 SERPINE1 (0.52) HPGDMAPTTP53HSD17B10NPSR1
SCHEMBL1015322 0.78 ALDH1A1 (0.54) HPGDMAPTTP53HSD17B10NPSR1
SCHEMBL420125 0.77 SERPINE1 (0.67) MAPTPPARGSERPINE1GAA
SCHEMBL7039697 0.77 PPARG (0.82) MAPTPPARGSERPINE1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US claimed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US claimed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP claimed
US-10092537-B2 Use for PAI-1 inhibitor RENASCIENCE CO., LTD. (JP) 2018-10-09 US disclosed
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2016-06-09 US disclosed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 HPGD 683/4885MAPT 3139/4885TP53 2148/4885
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 HPGD 502/4885MAPT 4320/4885TP53 468/4885
US-10092537-B2 Use for PAI-1 inhibitor SERPINE1, SERPINC1, SERPINB1 HPGD 345/4885MAPT 4126/4885TP53 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.